What is USIOL?
Established in 1985, USIOL has carved a niche in the global market by producing a comprehensive range of intraocular lenses, injectors, viscoelastic gels, and sutures. The company's unwavering commitment to quality and regulatory adherence is underscored by its FDA registration and ISO 13485 certification. This focus on compliance ensures that ophthalmologists worldwide receive superior products, backed by responsive customer service. USIOL's operational longevity and established product lines position it as a reliable entity within the ophthalmic device manufacturing industry.
How much funding has USIOL raised?
USIOL has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in USIOL
PPP
Public-Private Partnership
What's next for USIOL?
The recent strategic investment, characterized as a major capital injection, signals USIOL's readiness for its next phase of growth. As a company operating in the late-stage funding environment, this financing is likely earmarked for scaling production capabilities, enhancing research and development for next-generation intraocular lens technology, or expanding its global market reach. The strategic nature of the backing suggests alignment with investors who see significant potential in USIOL's established market position and its capacity for innovation in the ophthalmology field.
See full USIOL company page
